The Office of the Inspector General’s audit report on the Global Fund grants to Sudan provides a picture of the difficulties of implementing disease programmes in a challenging operating environment. Given the situation, it is encouraging that financial management and oversight are judged to be satisfactory. However, the sad reality is that the disease programmes are not on course to achieve the 2025 and 2030 targets; and, with the recurring government changes at central and state levels, satisfactory and timely completion of the agreed management actions is unlikely. The report also includes some inconsistencies that will raise questions in the mind of the careful reader.
On 4 April 2023 the Office of the Inspector General (OIG) published its report on the Global Fund grants to Sudan during the period January 2020 to December 2021.
The Global Fund has classified Sudan as a challenging operating environment (COE) due to the country’s history of civil war and political instability. Economic and political instability continued during the audit period. Inflation more than doubled from 163% in 2020 to 359% in 2021, owing to currency depreciation and removal of fuel subsidies. The report states that this impacted government spending on health care (reduced from $159 per capita in 2014 to $47 in 2019), which limited the population’s access to services. The World Bank database is quoted as the source but, in July last year, that database showed government expenditure on health to have been $29.6 in 2014 and $10.6 in 2019. Those figures were subsequently revised so that the current database reports them to have been $23.4 in 2014 and $7.8 in 2019, and to have slightly risen to $8.0 in 2020.
The report notes that active grants totalled $170 million for the 2020-2022 funding allocation period (i.e., January 2021 to December 2023 implementation period), of which 64% had been disbursed by end December 2021. However:
The Federal Ministry of Health (FMOH) and the United Nations Development Programme (UNDP) are the Principal Recipients (PRs) for malaria and HIV/TB, respectively. Grants are also implemented via the Sudan Disease Control Directorate of FMOH for HIV, TB, and malaria (acting as a Sub-Recipient).
Progress in fighting HIV, TB and malaria is summarised in the following table that is presented in the report:
The objectives of the audit were to assess the adequacy and effectiveness of:
Although significant costs of $10 million between NFM2 and NFM3 have been sustained to address supply chain gaps, including operational costs, there is little evidence of improvement. Weak oversight associated with lack of supportive supervision at the sub-national level, and low human resource capacity at all supply chain levels, are affecting health commodity traceability, availability, and accountability. This has contributed to material levels of expiries and stock-outs.
Procurement and distribution of health products constitute 71% ($140.6 million) of NFM3 grants to Sudan, with the United Nations Children's Fund (UNICEF) procuring malaria commodities and UNDP procuring for TB and HIV. Health commodities, except long-lasting insecticidal nets (LLINs), are stored and distributed by the National Medicines Supplies Fund (NMSF), which has a network of 18 regional warehouses.
The OIG noted:
Despite substantial Global Fund investments ($353 million since 2015) in malaria, programmatic results have remained stagnant. Grant performance and impact are undermined by sub-optimal conditions for implementation, insufficient PR oversight from state to health facility levels and the limited funding landscape. Given the current trend, Sudan may not be able to reduce malaria morbidity and mortality by 30% by 2025.
The report explains that:
The third finding is that HIV programme performance is inadequate. HIV outcomes have improved in Sudan with a decrease in HIV/AIDS-related deaths by 17% since 2017. In 2020, the government updated its antiretroviral treatment (ART) guidelines to include community activities and expanded the scope of community-based organizations in HIV service delivery. While notable, this progress is insufficient to achieve the 95-95-95 target by 2025 and eliminate HIV as a public health threat by 2030. Sudan’s limited progress is illustrated in the following figures that compare its performance with the regional average:
OIG attributes this inadequate performance to:
Improvement is needed in the Global Fund’s approach to leveraging the COE policy in Sudan, especially during emergencies. The Secretariat’s approach, in-country oversight and implementation arrangements have not adequately leveraged the principles of flexibility, innovation and partnerships that the COE policy encourages. The use of a “developmental approach” to address humanitarian emergencies in Sudan has contributed to weak grant performance and limited progress against malaria and HIV.
The OIG gives the following examples where it considers the Global Fund could have leveraged flexibilities to increase the effectiveness of grant implementation:
Improvement is also needed in oversight and risk management. The report notes that:
Finally, OIG states that improvement is needed in assurance arrangements. The OIG reviewed 28% of the total transaction amounts managed directly by the FMOH from 2019 to 2021 and noted a considerable improvement in financial management at the Program Management Unit (PMU). Despite improvements in financial management since the last audit, the OIG observed that the Fiscal Agent does not conduct reconciliations between the approved transactions and those recorded in the PR’s general ledger. This makes it impossible to provide assurance on the completeness and accuracy of the financial information reported to the Global Fund.
In terms of the audit objectives, OIG’s overall assessment was that:
.
The agreed management actions (AMAs) for each of the four findings are as follows:
This audit report provides an insight into the difficulties of implementing disease programmes in a country classified as a COE and also demonstrates how the Secretariat has difficulties in applying the COE policy flexibilities: raised many times both by the OIG and the countries themselves. . It is encouraging to read that the Global Fund has established sound control systems and processes in grant management to reduce financial and fiduciary risks in Sudan. The FMOH had established a PMU that provides overall financial management and oversight of the Global Fund grants to the FMOH and ensures timely completion of financial reporting. The grants also have a Fiscal Agent that oversees financial management procedures, including monitoring program activities and verifying financial transactions. The Fiscal Agent applies an oversight protocol manual when conducting quality checks at different levels. The Fiscal Agent has also improved the timely reporting to the Global Fund Country Team.
It is therefore a pity that parts of the report are confusing. For example, in the opening summary, it states that “The flexibility, innovation, and partnership principles that the Global Fund COE policy allows have yet to be effectively leveraged in Sudan”. It then immediately continues: “Although the OIG noted considerable improvement in financial management, innovative and flexible solutions are ineffective to address data quality challenges, to increase the use of malaria rapid diagnostic tests, to improve vector control interventions, or to increase grant oversight beyond the state level.” So, if innovative and flexible solutions are ineffective for these purposes, why, as later recommended, continue to try to use them?
Another example is that in its comment on the need for significant improvement in programme management, the report states that “The Secretariat could have worked continuously with the government to find a suitable substitution for the indoor residual spray intervention.” Yet, a few pages later, the report acknowledges that “Since the first coup in 2019, there have been many changes in leadership in the Federal Ministry of Health, with seven ministers of health, four global health directors and three disease control department heads. This instability has undermined accountability and implementation of grant activities.” How then could the Secretariat have worked ‘continuously’ with a government that was – and still is – ever changing? This is an important issue because it could affect successful completion of the AMAs.
In the section on key issues and risks, the report tells us that “The program has no operational plan for malaria case management and has not led a malaria review meeting in five years within the audit period”. This sounds strange for several reasons. First, the country’s funding request for the malaria grant would only have been approved had there been a program plan in place and, if there had been a significant gap in that plan, the TRP would have noted it and required it be attended to. Second, the malaria funding request could not have been prepared and submitted without some form of review. Third, a program cannot lead a meeting. It is also clumsy to refer to “five years within the audit period” when that period was only two years.
The report raises the issue of ineffective distribution which was observed during the visits to HFs. In the section on objectives and scope, the report states that “Our auditors visited 19 health facilities in 6 of the 18 states in Sudan, as well as five warehouses belonging to the National Medical Supplies Fund”. That means that the auditors visited less than 1% of HFs. Given such a small sample, their findings – however valid – cannot be assumed to be representative. In the discussion of the first finding, it states that "in the first four states visited, only 15 vehicles were available to deliver to 1,450 health facilities and 31 localities, with 20% of the vehicles not functioning". It is surprising that there was no further comment on the shortage of vehicle availability which, logically, would go some way to explaining stock-outs. Also, in the reference to the number of available vehicles, it is unclear if they are owned by the NMSF or HFs. So who is short of what?
References to the PRs are very confusing. The audit is stated to have covered the PRs and Sub-Recipients (SRs) of the Global Fund supported programmes. However, this was not strictly the case as the report discloses that: (a) the OIG did not audit expenditure of UNDP, which is the PR for the HIV/TB grants, as the UN and its subsidiaries do not consent to third parties accessing their books and records; and (b) the OIG was not granted access to the supporting documents of sub-sub-recipients managing HIV activities, due to the refusal of the United Nations Population Fund (UNFPA), UNDP's SR. This means that the audit findings on financial assurance relate to the malaria grant, which is 54% of the portfolio.
In the first AMA, it is evident that the PR referred to is the FMOH. However, the second AMA, which is all about malaria, states that the Secretariat will, in collaboration with the PR (which is the FMOH), support the FMOH. That makes no sense. The third AMA, which relates to the HIV findings, refers to the ‘relevant PRs’ when the relevant PR for the HIV/TB programme is UNDP.
The fourth AMA includes assessing grant design. In a COE situation, no amount of designing will ensure success without stability, the necessary resources and accountability in place. The AMA is also supposed to involve the development of ‘an innovative solution’. What is then listed are not innovative but the usual common-sense steps. Proven approaches are indeed more likely to succeed than expending effort and scarce resources trying to invent innovative solutions in a situation that is not amenable to change. But neither proven nor innovative solutions will make a difference when, as noted above, the ongoing leadership changes within the FMOH and state governments contribute to poor grant performance.
Finally, the table showing progress in fighting the diseases uses different time scales that are not all relevant to the current grants. It would be more appropriate and informative to compare – or at least include – the progress on each of the diseases since the time of the previous audit.
No comments yet. Be the first to comment!